Not a Normal 20 Year Anniversary for Cmed
HORSHAM, England, October 13, 2020 (Newswire.com) - Cmed, a full-service technology-led CRO that specializes in oncology, immuno-oncology, cell and gene therapy and rare diseases is celebrating its 20 year anniversary.
These are not normal times and Cmed is not a normal CRO or technology provider. Instead, it has spent the last 20 years preparing for the “new normal”. Starting as a Data Specialist CRO handing paper CRFs in a barn-converted office, Cmed has spent 20 years preparing for and living the “new normal”. Cmed now operates one of the most advanced and sophisticated clinical data platforms in the world, encapsia, built upon its own expertise with a vision of being able to capture, manage, interpret and analyze all clinical data live, from any source. Now with hundreds of staff and operating on a global scale, Cmed continues to provide expertise in data and analytics, but is also a specialist full-service CRO running oncology and rare disease studies.
“We combine our expertise and technology with our values,” according to COO Stephanie Langouet. “Too many CROs forget they are engaged to provide a service. While delivery remains an absolute mandate for Cmed, we make it our mission to provide our clients an experience that is collaborative, flexible and positive. We even include this in our company’s Guiding Principles that all employees sign up to.”
“We are different in many good ways,” said Chief Technology Officer Timothy Corbett-Clark. He went on to say “people in the industry have been talking about the disruption caused to clinical trials by COVID-19, the challenges caused by managing the uncertainty and the new normal. We don’t see esource, home-based data capture, remote source data verification, clinical data science or applying virtualization, decentralization or Artificial Intelligence as anything but normal! It is the way it should be, and more. We have been following this vision and path for twenty years. It is why we built encapsia.”
At the core of Cmed’s vision is to run clinical trials better, and to help and save lives. For studies of COVID-19, Cmed offers services on a not for profit basis and provides encapsia license-free for capturing and managing clinical data.
Wrapping up, CEO and Founder David Connelly said, “I am proud of Stephanie, Tim, my team, employees and former employees. I am equally very grateful to our clients and those that have helped and believed in us. I am also excited about the future and our ability to deliver the new normal and beyond.”
Source: Cmed Group